Literature DB >> 14760885

Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.

Piero Colombatto1, Luigi Civitano, Filippo Oliveri, Barbara Coco, Pietro Ciccorossi, Diego Flichman, Mario Campa, Ferruccio Bonino, Maurizia Rossana Brunetto.   

Abstract

BACKGROUND AND AIMS: Standard models simulate the dynamics of hepatitis C virus (HCV) infection using HCV RNA kinetics and show a correlation between the clearance of infected hepatocytes and response to interferon. However, they are unable to predict whether the response will be maintained. The aim of our work was to identify criteria by which sustained responses may be predicted and defined.
METHODS: In our model the clearance rate of infected cells is a function of their number and the baseline rate is computed by the alanine aminotransferase (ALT) kinetics during the first month of therapy. We simulated the variations of viral and infected cell loads in 31 consecutive patients treated with IFN-alpha2b 3-5 MU every other day, with or without ribavirin, for 6 or 12 months depending on HCV genotype.
RESULTS: At baseline the computed (in 28 of 31 cases) percentage of infected cells was lower in seven sustained responders (mean: 11.7%, range: 1-24.6%) than in 14 transient responders (mean: 28.2%, range: 7.4-75.5%) and in seven non-responders (mean: 41%, range: 8.8-86%) (P=0.036). At the end of therapy the computed infected cell number was <100 cells/ml of extracellular fluid in all sustained responders (mean: 18.4, range: 1.7-48), in three transient responders (mean: 3500, range: 1.52-17500) and in none non-responders (mean: 28500, range: 1200-96000) (P=0.003). Overall of 10 patients with less than 100 infected cells/ml at the end of therapy seven (six had combination therapy) showed sustained response. All three relapsers received interferon monotherapy.
CONCLUSION: The analysis of infected cells dynamics using the new model might be useful to tailor treatment duration in patients with combination therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14760885

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  11 in total

1.  Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Authors:  Harel Dahari; Jeremie Guedj; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2011-07-02

2.  Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.

Authors:  Srunthron Akkarathamrongsin; Sunchai Payungporn; Vo Duy Thong; Kittiyod Poovorawan; Phisit Prapunwattana; Yong Poovorawan; Pisit Tangkijvanich
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Hepatitis C Viral Kinetics in Special Populations.

Authors:  Harel Dahari; Jennifer E Layden-Almer; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2008

4.  Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response?

Authors:  C Turbide; C Soulellis; M Deschênes; N Hilzenrat
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

5.  Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.

Authors:  Harel Dahari; Arthur Lo; Ruy M Ribeiro; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-03-14       Impact factor: 2.691

6.  A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.

Authors:  Harel Dahari; Jennifer E Layden-Almer; Eric Kallwitz; Ruy M Ribeiro; Scott J Cotler; Thomas J Layden; Alan S Perelson
Journal:  Gastroenterology       Date:  2009-01-01       Impact factor: 22.682

7.  Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.

Authors:  He-Chuan Wang; Yu-Peng Ren; Yue Qiu; Jenny Zheng; Gai-Ling Li; Chuan-Pu Hu; Tian-Yan Zhou; Wei Lu; Liang Li
Journal:  Acta Pharmacol Sin       Date:  2017-09-07       Impact factor: 6.150

8.  Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis.

Authors:  Maurizia Rossana Brunetto; Piero Colombatto; Ferruccio Bonino
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

9.  Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.

Authors:  Sheeja M Krishnan; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2011-02-03       Impact factor: 4.475

10.  HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial.

Authors:  P Colombatto; M R Brunetto; A M Maina; V Romagnoli; P Almasio; M G Rumi; A Ascione; G Pinzello; M Mondelli; L Muratori; R Rappuoli; D Rosa; M Houghton; S Abrignani; F Bonino
Journal:  J Viral Hepat       Date:  2013-08-27       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.